Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Overview of attention for article published in Blood, November 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 3 news outlets

Readers on

mendeley: 28 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Odronextamab Demonstrates Durable Responses in Patients With R/R FL, DLBCL in Ongoing Trial

Pharmacy Times, 02 Jul 2024

Image credit: Elnur | stock.adobe.com About the Trial Trial Name: A Study to Assess the Anti-Tumor Activity and Safety of…

Single-Agent Odronextamab Efficacy, Safety Upheld in Relapsed/Refractory DLBCL

Cancer Network, 10 Dec 2023

“Despite advances in care, the outcomes in relapsed/refractory diffuse large B-cell lymphoma are poor and there is a need for…

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

OncLive, 10 Dec 2023

Sabarish Ram Ayyappan, MD Odronextamab (REGN1979) produced durable responses and a generally manageable safety profile in…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.